Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

(2019) Nicholas Thatcher et al.   CLINICAL CANCER RESEARCH

Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar

(2019) Michael Thomas et al.   Immunotherapy

American Society of Clinical Oncology Statement: Biosimilars in Oncology

(2018) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab

(2018) Neungseon Seo et al.   mAbs

Rationale, Opportunities, and Reality of Biosimilar Medications

(2018) Gary H. Lyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects

(2018) Vladimir Hanes et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

489PFUNCTIONAL SIMILARITY ASSESSMENT RESULTS COMPARING BEVACIZUMAB TO BIOSIMILAR CANDIDATE ABP 215

(2017) T.L. Born et al.   ANNALS OF ONCOLOGY